Currently, the pathogenesis of chronic GVHD is unclear. To elucidate the molecular characteristics underlying chronic GVHD, we analyzed the gene expression profiles of 21 mononuclear cell samples from allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Self organizing map (SOM) clustering showed that the entire expression profiles of chronic GVHD samples were clearly different from those of the non-GVHD samples, and significance analysis of microarray (SAM) demonstrated that 120 genes, including PTDSS1, VAV1 and CD3D, were up-regulated, and 5 genes, including calnexin, were down-regulated in GVHD patients. Gene ontology annotation revealed that these genes are related to the phosphorous metabolism and lipid biosynthesis. Quantitative real time polymerase chain reaction (qRT-PCR) experiments validated the up-regulation of PTDSS1, VAV1 and CD3D in separate samples. Pathway-wise global test revealed that differential gene expression in cell cycle and T cell immune-associated pathways were significant between GVHD patients and non-GVHD patients. Seventeen classifier genes selected using a PAM (prediction analysis of microarray) algorithm showed favorable performance (prediction accuracy ¼ 0.85) for identifying patients with chronic GVHD. In conclusion, we identified differentially expressed genes and pathways in chronic GVHD patients using microarray analysis, and we also selected diagnostic genes predicting chronic GVHD status.
Introduction
Chronic GVHD, which is one of the most serious complications of allogeneic hematopoietic stem cell transplantation (HSCT), occurs in 20B70% of patients who survive for 100 days or more following the procedure. 1 The pathologic characteristics of chronic GVHD include immune dysregulation, immunodeficiency and impaired organ function, 2 and its treatment consists of the administration of immunosuppressive medications for approximately 1-3 years. 1 The high mortality associated with chronic GVHD makes it one of the major causes of death in stem cell transplant recipients. 3 However, the pathogenesis of chronic GVHD is still not well understood. 4 Although the true pathophysiologic mechanism of GVHD has not yet been fully clarified, alloreactive T cells are thought to initiate chronic GVHD. 2, 5, 6 Furthermore, humoral immunity-related phenomena, such as B cell dysfunction, a high prevalence of anti-nuclear autoantibodies, and clinical manifestations of autoimmune diseases are also observed in chronic GVHD patients. [7] [8] [9] Although these findings have been supported by individual studies, it has been difficult to perform a comprehensive study to examine these phenomena systematically. Therefore, in this study, we performed a microarray survey of peripheral blood samples obtained from chronic GVHD patients to elucidate the molecular characteristics underlying the pathogenesis of GVHD.
In the post-genomic era, microarray analysis plays a key role in the evaluation of whole genome mRNA expression. Due to its high throughput capacity, microarray experiments have yielded a large amount of previously unknown findings, and they are commonly used to identify diagnostic or prognostic biomarkers. For example, Golub et al. 10 identified diagnostic markers for distinguishing AML and ALL, as well as subgroups of ALL patients who had different cell lineages using only data obtained by conducting microarray analyses. Furthermore, analysis of gene expression profiles using microarray data have also identified global gene expression regulatory relationships, 11, 12 and may provide novel and holistic views regarding the molecular markers and mechanisms underlying pathologic processes. In this study, we evaluated peripheral blood samples obtained from 21 HSCT recipients using an oligonucleotide microarray that contained 20 142 probes to assess immunologic perturbation and other abnormal biologic processes associated with chronic GVHD. We also evaluated the results of the microarray analysis to determine if the gene expression profile could be used as a diagnostic tool for patients with chronic GVHD.
Materials and methods

Sample population
A total of 21 patients (median age; 42 years, range; 22-64 years) who received allogeneic HSCT between May 1991 and June 2005 at the Seoul National University Hospital, Seoul, Korea were evaluated using gene expression analysis. The characteristics of the GVHD and non-GVHD patients are shown in Table 1 . All patients had received HSCT from HLA (human leukocyte antigen)-matched sibling donors with the exception of 2 patients whose HLA were mismatched in one A locus. All patients were in complete remission and in the complete chimerism state. Eleven of the 21 patients developed chronic GVHD, including one who received partially mismatched transplantation. Protocols for all cases in this study were approved by the Institutional Review Board at the Seoul National University Hospital, and informed consent was obtained from all patients.
Target preparation
Two micrograms of total RNA were extracted from mononuclear cells of peripheral blood and added to a reaction mix with a final volume of 12 ml that contained T7-(dT) 24 oligonucleotide primer. The mixture was incubated for 10 min at 70 1C and then chilled on ice. While the mixture was on ice, 2 ml of 10 Â first-strand buffer, 4 ml of 5 mM dNTP mix, 1 ml of RNase inhibitor (40 U/ml) and 1 ml of Superscript II RNase H -reverse transcriptase (200 U/ml) was added to give a final volume of 20 ml. The mixture was then incubated for 2 h in a 42 1C water bath. Next, second-strand cDNA was synthesized in a final volume of 100 ml in a mixture containing 10 ml of 10 Â second-strand buffer, 4 ml of 5 mM dNTP mix, 2 ml of DNA polymerase mix (20 U/ml) and 1 ml of RNase H (2 U/ml) for 2 h at 16 1C. The cDNA was then purified using a Qiagen QIAquick purification kit, dried down, and resuspended in IVT reaction mix that contained 4 ml of 10 Â reaction buffer, 4 ml of 75 mM ATP, 4 ml of 75 mM GTP, 4 ml of 75 mM CTP, 3 ml of 75 mM UTP, 7.5 ml of 10 mM Biotin 11-UTP and 4 ml of enzyme mix with a final volume of 40 ml. The reaction mix was then incubated for 14 h at 37 1C and the cRNA target was purified using an RNeasy kit (Qiagen, Hilden, Germany). The cRNA yield was quantified by measuring the UV absorbance at 260 nm, and then fragmented into 40 mM Tris-acetate (TrisOAc, pH 7.9), 100 mM KOAc and 31.5 mM MgOAc at 94 1C for 20 min. This typically resulted in a fragmented target with a size range between 100 and 200 bases.
Array hybridization
Ten micrograms of fragmented target cRNA in 260 ml of hybridization solution was used for hybridization with each UniSet Human 20 K I Bioarray (Amersham Biosciences, Little Chalfont, Bucks, UK). The hybridization solution was heated to 90 1C for 5 min to denature the cRNA, and then chilled on ice for 5 min. Next, the sample was vortexed for 5 s at maximum speed, and 250 ml was injected into the inlet port of the hybridization chamber, which was then placed in a 12-slide shaker tray. The hybridization chamber ports were then sealed with 1 cm sealing strips (Amersham Biosciences), and the shaker tray containing the slides was loaded into a shaking incubator. The slides were then incubated for 18 h at 37 1C while shaking at 300 r.p.m.
Post-hybridization processing using Cy5-streptavidin The 12-slide holder was removed from the shaking incubator and the hybridization chamber was then removed from each slide. Next, each slide was briefly rinsed in TNT buffer (0.075 M Tris-HCl pH 7.6, 0.1125 M NaCl, 0.0375% Tween 20) at room temperature, and then washed in TNT buffer at 42 1C for 60 min. The signal was then developed using a 1:500 dilution of Cy5-streptavidin (Amersham Bioscience) for 30 min at room temperature. Excess dye was removed by washing the slide four times 
Data analysis
To remove the systemic error and bias of the microarray experiment, variable stabilizing normalization (VSN) 13 and the quantile normalization method 14 were applied to the scanned probe intensities. Missing value estimation was then performed using the k-nearest neighbor (KNN) method, 15 and only genes that had missing values for less than 20% of the total samples were considered in the estimation. Consequently, 18 356 probes (91.1% of the total probes) were used in the analysis. Vendor-provided probe information was used for mapping each probe to the GenBank accession number. Collection of the available pathways and microarray probe mapping to the gene members of the each pathway were performed using the ArrayXpath knowledge base, 16 and a total of 460 pathways were used in the analysis. We tested the hypothesis that the global gene expression pattern of mononuclear cells was different between GVHD and non-GVHD patients using sample-wise, self organizing map (SOM) clustering. A linear grid based on the direction of the first two principal components was used to initialize SOM clustering. The learning rate and neighborhood function used were the inverse-time and Gaussian function, respectively.
Significance analysis of microarray (SAM) was performed to identify the differentially expressed genes (DEGs) in GVHD patients. 17 After 1000 times permutations, DEGs with a false discovery rate (FDR) level of 0.005 were obtained. In microarray experiments, large numbers of genes can be identified as significantly changed, however it is cumbersome to investigate and infer the relationship between the DEGs and pathophysiology of chronic GVHD. Therefore, functional annotation with gene ontology (GO) is used to manipulate the problem. The DAVID (the database for annotation, visualization and integrated discovery) web site was used to annotate the DEGs with the GO biologic process terms to infer the tentative biological mechanisms involved in GVHD. 18 A global test was then applied to explore the differentially expressed pathways. 19 The global test is a modified generalized linear model (GLM) approach for microarray data analysis, which was developed to overcome limits of the single gene-wise analysis of microarray data. This method can utilize predefined gene sets that are extracted under the biological context. To analyze the data generated in this study, we defined biological pathways as gene sets and then tested whether each pathway was differentially expressed in GVHD patients. An adjusted p value was obtained using the Bonferroni correction procedure to account for multiple testing. Biomarker genes and statistical models for predicting disease status were then extracted using the PAM (prediction analysis of microarray) algorithm. 20 The selection criterion for shrinkage was the minimal number of genes and the highest prediction accuracy. The R 2.4.1 package (The Comprehensive R Archive Network (CRAN), http://cran.r-project. org/) was used for all statistical analyses.
Results
Global gene expression profile
The result of SOM clustering showed that the whole mRNA expression profile of mononuclear cells obtained from GVHD patients differed from those obtained from non-GVHD patients. In the result map, samples obtained from GVHD patients revealed a tendency to cluster together as well as separately from samples obtained from non-GVHD patients ( Figure 1 ).
Differentially expressed genes in samples obtained from GVHD and non-GVHD patients Among 18 356 probes, the SAM method identified 125 probes as DEGs with 1,000 permutations and a FDR of 0.005. Of these genes, 120 were up-regulated and 5 were down-regulated in the samples obtained from GVHD patients. Phosphatidylserine synthase 1 (PTDSS1) was the most up-regulated gene in the GVHD group, and the pleckstrin homology domain containing family B (evectins) member 1(PLEKHB1), cyclin dependent kinase 6(CDK6), and Vav 1 oncogene (VAV1), were the highest ranked upregulated genes in samples obtained from the GVHD patients. Calnexin (CANX) was the most down-regulated gene in the GVHD patient samples. Eukaryotic elongation factor-2 kinase (EEF2 K), and transducin-like enhancer of split 3 (TLE3) were also highly down-regulated in the GVHD specimens (Table 2, Figure 2 and Supplementary data).
Gene ontology enrichment study was performed to define the molecular characteristics of DEGs. The following six biological process (BP) terms were found to be significant: the frizzled signaling pathway, phosphorous metabolism, phosphate metabolism, phosphorylation, protein amino acid phosphorylation and lipid biosnythesis. When molecular function terms were applied, 9 terms were found to be significant: transferase activity, protein serine/ threonine kinase activity, kinase activity, GTPase regulator activity, N-acetylglucosamine 6-O-sulfotransferase activity, protein kinase activity, sulfotransferase activity, transferase activity, transferring sulfur-containing groups, transferase activity and transferring phosphorus-containing groups (Table 3) .
Differentially expressed pathways in samples obtained from GVHD and non-GVHD patients
The global test conducted to examine the expression profile of 460 pathways with Bonferroni's multiple testing correction revealed that difference of gene expression of 30 pathways were statistically significant (Table 4 , Po0.00012 after adjustment). These pathways can be categorized into 5 groups: cell-cycle associated pathways, cell mediated immune associated pathways, cell motility associated pathways, myogenesis associated pathways and other pathways.
In the cell cycle-related group, the following pathways, which were associated with the transition of cells in the G1 phase into the S phase, were identified: the 'Cell Cycle: G1/S Check Point' pathway, 'Influence of Ras and Rho proteins on G1 to induce the transition to the S phase' and the 'RB Tumor Suppressor/Checkpoint Signaling pathway that is activated in response to DNA damage'. Of the cell cycle associated pathways, the 'Cell Cycle: G1/S check point' pathway was the most significant pathway identified in the analysis (P ¼ 0.0000013).
When the immune-related pathways were considered, many T cell associated pathways were identified, including the 'T Cell Receptor Signaling' pathway, 'Lck and Fyn tyrosine kinases involved in the initiation of TCR Activation', 'T Cytotoxic Cell Surface Molecules', and 'T Helper Cell Surface Molecules' pathway. Further, the 'IL 2 signaling' pathway and the 'Ras-Independent pathway in NK cell-mediated cytotoxicity' were also related to the T cell immune process. In addition, the 'Fc Epsilon Receptor I Signaling in Mast Cells' pathway, which is part of B cell-mediated immunity, was also found to be significant.
The motility-related pathways included the 'S1P_Signal-ing' and 'Rac 1 cell motility signaling' pathways. The 'Signal Dependent Regulation of Myogenesis by Corepressor MITR', 'ALK in cardiac myocytes' and 'Control of skeletal myogenesis by HDAC & calcium/calmodulindependent kinase' pathways were found to be significant in the myogenesis related group.
The remaining pathways identified included the phospholipase C signaling pathway, which was related to signaling process, the estrogen-responsive protein Efp, which controls the cell cycle and breast tumor growth, and the pathway that controls androgen, estrogen and sulfur metabolism.
Validation of microarray experiments using qRT-PCR
The microarray results were confirmed in 19 samples (10 non-GVHD and 9 GVHD samples) not included in the microarray experiment using qRT-PCR. The Mann-Whitney test revealed that the expression levels of PTSSD1, VAV1 and CD3D were significantly different in the GVHD positive and negative groups (Po0.001, Figure 3 ).
Classification analysis
After the initial PAM procedure was conducted, the prediction accuracies according to the shrinkage level and corresponding gene set were determined. When a shrinkage threshold of 3.5 was used, 17 genes yielded the best classification performance, which was 85% prediction accuracy with a 10 fold cross validation (Figure 4 ). These genes included phosphatidylserine synthase 1, pleckstrin homology domain containing family B (evectins) member 1, cyclin-dependent kinase 6, vav 1 oncogene, mitochondrial ribosomal protein L19, MRNA (clone ICRFp507I1077), coiled-coil domain containing 6, immunoglobulin superfamily member 4B, Homo sapiens AOC3 gene for vascular adhesion protein-1 exon 2, leucine rich repeat containing 27, chromosome 10 open reading frame 75, RCD1 required for cell differentiation1 homolog (Schizosaccharomyces pombe), phospholipase A2, group The score represents the results of a statistical test by the SAM to evaluate the difference in expression between non-GVHD and GVHD specimens. The fold change is the ratio of average expression values of non-GVHD specimens to those of GVHD specimens. A positive and negative score indicates upregulation and down-regulation in the GVHD specimens, respectively. Full list of the SAM result is in the supplementary data.
IIF KIAA0427, HCF-binding transcription factor Zhangfei, RAP1A member of RAS oncogene family, and ring finger protein 144. The sensitivity and specificity of the classifier genes were 0.82 and 0.90, respectively.
Discussion
In this study, we screened genes obtained from peripheral blood mononuclear cells to elucidate the molecular signature associated with the pathogenesis of chronic GVHD. To date, few microarray experiments regarding GVHD have been conducted, and to the best of our knowledge, this is the first report that investigated gene expression profiles in chronic GVHD patients using microarray technology. This analysis revealed many consistent and novel findings related to the pathogenesis of chronic GVHD.
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SOM clustering was performed to delineate the global gene expression profiles of chronic GVHD patients and non-GVHD patients, and our results showed that non-GVHD and GVHD samples tended to aggregate separately. The clustering pattern indicated that the microarray analysis was capable of discriminating GVHD status without any other clinical information, which may be considered as fundamental evidence that information The number of genes indicates the number of member genes in each pathway. The pathways were collected from the BioCarta (www.biocarta.com), KEGG (www.genome.jp/kegg/) and PharmGKB (www.pharmgkb.org) web sites. Assignment of microarray probes to the corresponding pathways was performed via the ArrayXPath knowledge base. contained in microarray data is important and useful for the elucidation of the pathophysiology of chronic GVHD. Among the genes differentially expressed in GVHD samples, phosphatidylserine synthase 1 (PTDSS1), which is known to be related to phospholipid biosynthesis, was the most up-regulated (SAM score ¼ 4.467, fold change ¼ 5.109). It is well known that apoptosis plays a key role in the pathogenesis of chronic GVHD 21 and that phosphatidylserine inhibits immune responses by mediating the recognition and engulfment of apoptotic cells. 22 Therefore, increased expression of PTDSS1, as shown in our study, may indicate a protective response against the overwhelming apoptotic process in GVHD.
VAV1 (SAM score ¼ 4.281, fold change ¼ 4.940) is a notable DEG because it has been reported to be a member of many immune-related pathways, such as B and T cell receptor signaling, 23, 24 natural killer cell mediated cytotoxicity, 25 and leukocyte transendothelial migration. 26 Since these immunologic processes are essential elements of GVHD, our findings may indicate that VAV1 is one of the key signaling molecules involved in the pathogenesis of GVHD. CD3D (SAM score ¼ 3.021, fold change ¼ 2.338) plays a role in the maturation of T cell development. 27 Increased expression of the CD3D gene indicates that T cell recruitment is active in GVHD patients, which supports the findings of previous studies. 28 Up-regulation of the above 3 DEGs, which had not been studied in chronic GVHD, was validated by qRT-PCR. The differences in mRNA expression between groups were statistically significant for all of the genes tested (Po0.001). Since independent samples that were not included in the microarray analysis were used in the analysis, our data strongly indicate that the molecules are associated with the pathogenesis of chronic GVHD.
Our study showed that the CXCL13 gene was overexpressed in patients with chronic GVHD (score ¼ 2.84, fold change ¼ 2.40). CXCL13 is a highly effective attractant of human blood B lymphocytes, 29 and its overexpression has been reported in many autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, lupus nephritis, Sjogren's syndrome and myasthenia gravis. [29] [30] [31] [32] [33] Similarity of the symptoms between the aforementioned diseases and chronic GVHD suggests that CXCL13 may be responsible for inducing migration of B cells to the target tissues in chronic GVHD. While the roles of various chemokines in leukocyte trafficking and migration of donor T cells to the target tissues of GVHD have been studied, the roles of B cell chemokines have not been investigated in depth with regard to the pathogenesis of GVHD. Although its expression was not validated by the PCR experiment, the role of CXCL13 in the humoral immune system as it relates to the pathogenesis of chronic GVHD warrants further study. Although the function identification of individual DEG provides information about biological processes involved in the pathogenesis of GVHD, the molecular signatures were analyzed using gene ontology enrichment test in an attempt to gain a better understanding. Among significant terms, phosphorous and phosphate metabolism were the biological processes term found to have the largest number of annotated genes. Since the phosphorus-related metabolic process is connected with many signaling processes, the DEGs mapped to the phosphorus-related metabolic process terms included diverse signaling processes members, such as cyclin dependent kinase 6 (CDK6), p21 activated kinase 6 and testis specific kinase 6. Although the meaning of these results as they relate to chronic GVHD is not clear, these terms seem to be the consequence of cell cycle and immunologic processes. 22, 34, 35 Additionally, the molecular terms were consistent with the biological process terms and included many kinase and transferase activity terms.
In addition to the functional annotation of DEGs, we analyzed pathway-wise gene expression using a global test to clarify the molecular characteristics underlying the pathogenesis of chronic GVHD. The global test using the pathway information can identify the biological pathways which are differentially expressed. Moreover, group-wise testing can identify differentially expressed pathways, which are not readily identified by single gene-wise analysis. 19 The results of the global test indicated that many T cellrelated pathways were significantly expressed in patient samples, including the T cell receptor signaling pathway, the T helper cell surface molecule pathway, the Ras independent pathway involved in NK cell mediated cytotoxicity, and the IL-2 signaling pathway (Table 3) . It is well known that donor-derived alloreactive T cells play a major role in the pathogenesis of chronic GVHD 36 and our results also documented the activation T cell-mediated immune processes in chronic GVHD development. Prior studies have reported the following sequence of biological phenomena in chronic GVHD: The donor T cell receptor recognizes the host MHC antigen and is then activated and differentiated into a T helper cell via the T cell receptor signaling pathway. Donor T helper cells are then activated upon recognition of the alloantigen, and in turn secrete IL-2 and IFN-g, which recruit other T cells, cytotoxic T lymphocytes, natural killer (NK) cells and monocytes. The elements of this process sequence could be identified in the results of the global test.
It is interesting to note that the Fc Epsilon Receptor I Signaling in Mast Cells pathway, which is involved in the B cell immune process, was differentially expressed. Although it did not pass the Bonferroni correction, the p value of the B cell receptor signaling pathway was considerably low (P ¼ 1.30E-5). These findings and the overexpression of CXCL13 may indicate the involvement of the B cell immune process in the pathogenesis of GVHD.
Interestingly, the global test showed that the cell cycleassociated pathways were differentially expressed in concordance with the SAM results. These novel findings appear to be related to the activation of T cell differentiation in response to antigenic stimulation. In this study, many cell cycle-related genes and pathways were shown to be differentially expressed in chronic GVHD specimens, especially those associated with G1 to S progression. The CDK6 gene, which regulates cell cycle progression from the G1 phase to the S phase, was highly overexpressed in GVHD samples (score ¼ 4.29, fold change ¼ 4.86). The association between CDK6 and the G1/S transition of T lymphocytes was reported in a previous study. 37 When the global test was conducted, the 'Cyclins and cell cycle regulation', 'Cell Cycle: G1/S Check Point' and 'Influence of Ras and Rho proteins on G1 to S transition' pathways were also differentially expressed in chronic GVHD patients. All of these pathways are associated with cell cycle progression from the G1 phase to the S phase, and the 'IL-2 signaling' pathway, which promotes the G1-to-S transition 38 was also differentially expressed in the global test. Based on these findings, we suggest that cell cycle progression from the G1 phase to the S phase may be a critical step for activation of immune related cells in the pathogenesis of chronic GVHD.
The 'S1P_Signaling' and 'Rac 1 cell motility signaling' pathways play a role in cell movement, and are associated with the recruitment of immune cells to target organs. 39 In addition, myocyte-associated pathways are linked with MEF2 (myocyte enhancer factor 2), which mediates the apoptosis of T cells. 40 These pathways may be another targets for the management of GVHD because the perturbation of thymic T cell apoptosis is one of the characteristic features of GVHD. 41 In this study, we used the peripheral blood sample without consideration of proportion of lymphocyte subtypes (T, B cell and monocyte etc.). We had tried to sample the subtypes of lymphocyte separately, but we found that it required larger amount of blood sample and more cost. Furthermore, it is possible that the separation procedure of lymphocyte subtypes increases experimental bias. Besides, although the proportion of lymphocyte subtypes was not measured explicitly in this analysis, it seems to have little effect on the result of DEGs and differentially expressed pathway analysis because maker genes of each subtype of lymphocyte were not differentially expressed (See Supplementary Table 3 ). Most of the marker genes were not in our DEG list, except CD3D. These findings indicate that the DEGs and differentially expressed pathways did not result from difference of proportion of lymphocyte subtypes between GVHD and non-GVHD patients. To validate our speculation, we performed linear regression analysis between each of 125 DEGs and the marker gene set expressions. Significant result implies that the DEG's expression level can be explained by the maker genes' expression level, which means proportion of lymphocyte affects the DEG's expression. All the DEGs' expression could not be explained by the maker gene expression levels (Supplementary Table 4 ). Based on these findings, we concluded that our analysis result was independent on the proportion of lymphocyte subtypes. To find which lymphocyte subtype has a role in expression of the DEGs is main goal of our next research.
The classifier gene set comprised of 17 genes which were selected using the PAM algorithm showed a favorable classification performance. The results indicate that chronic GVHD can be diagnosed using gene expression values of these classifier genes in peripheral blood mononuclear cells. The value of these classifier genes for the early diagnosis and management of chronic GVHD needs to be evaluated in a larger number of patients, preferably in a prospective study.
In conclusion, we have identified molecular characteristics and diagnostic markers for chronic GVHD using an oligonucleotide microarray. Many immune and cell cycle related genes and pathways were differentially expressed in chronic GVHD patients. These results appear to indicate that alloreactive T cell activation through the T cell receptor signaling pathway and cell cycle progression are the main mechanisms responsible for chronic GVHD induction and maintenance. Our results also indicated the possibility of B cell involvement in the manifestation of the autoimmune disorder-like symptoms associated with chronic GVHD.
